Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Bicycle Therapeutics plc

Market Cap 286M 248M 229M 215M 401M 27.41B 409M 2.73B 1.06B 13.21B 1.07B 1.05B 45.93B P/E Ratio 2026 *
-1.74x
P/E Ratio 2027 * -1.91x
Enterprise Value -226M -196M -181M -169M -316M -21.62B -323M -2.15B -834M -10.42B -848M -829M -36.23B EV / Sales 2026 *
-12x
EV / Sales 2027 * -8.36x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+1.74%
1 week-3.98%
Current month-12.58%
1 month-12.77%
3 months-21.90%
6 months-44.82%
Current year-42.09%
1 week 3.97
Extreme 3.97
4.26
1 month 3.97
Extreme 3.97
4.78
Current year 3.97
Extreme 3.97
7.34
1 year 3.97
Extreme 3.97
9.18
3 years 3.97
Extreme 3.97
28.91
5 years 3.97
Extreme 3.97
62.08
10 years 3.97
Extreme 3.97
62.08
Manager TitleAgeSince
Chief Executive Officer 57 2015-08-31
Director of Finance/CFO 46 2026-01-28
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 57 2025-06-16
Director/Board Member 63 2021-03-16
Director/Board Member 69 2019-07-17
Date Insider Type Main position Quantity % Market Cap.
04-01Sell

Chief Technology Officer

2,404 0.0063%
04-01Sell

Chief Financial Officer

901 0.0024%
04-01Sell

Chief Operating Officer

1,408 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%-3.98%-53.20%-84.20% 286M
+0.39%+1.78%+54.13%+110.70% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+3.81%-5.07%+12.00%-29.52% 15.79B
+0.09%+0.28%+8.86%-40.17% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+5.27%+5.54%+14.25% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +1.70%-0.78%+18.58%+84.21% 21.02B
Weighted average by Cap. +1.51%+0.76%+31.45%+97.64%

Financials

2026 *2027 *
Net sales 18.89M 16.39M 15.11M 14.16M 26.45M 1.81B 27M 180M 69.77M 872M 70.9M 69.37M 3.03B 14.11M 12.25M 11.29M 10.58M 19.76M 1.35B 20.18M 135M 52.14M 651M 52.98M 51.84M 2.26B
Net income -155M -135M -124M -116M -218M -14.88B -222M -1.48B -574M -7.17B -583M -571M -24.94B -165M -143M -132M -124M -232M -15.83B -236M -1.58B -611M -7.63B -621M -607M -26.53B
Net Debt -512M -444M -410M -384M -717M -49.02B -732M -4.89B -1.89B -23.63B -1.92B -1.88B -82.17B -404M -351M -323M -303M -566M -38.7B -578M -3.86B -1.49B -18.65B -1.52B -1.48B -64.86B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
26-06-12 4.050 $ -1.22% 24,344
26-06-11 4.100 $ +1.74% 651,388
26-06-10 4.030 $ -3.36% 238,103
26-06-09 4.170 $ +1.46% 673,323
26-06-08 4.110 $ -2.14% 259,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.100USD
Average target price
12.62USD
Spread / Average Target
+207.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!